Table 3.
Known group validity testing: Effect sizes for the differences within the prostate cancer sample between subgroups formed on the basis of comorbidity status, age, education and marital status
| PCa survivors | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Co-morbidities | Age | Education | Marital status | |||||||
| 0–1 comorbiditiesa | 2 or more co-morbidities | Younger than 70a | 70–80 | 80 and older | Universitya | College and high school | Primary school only | Singlea | Partner | |
| SF36: Physical Functioning | −0.60 | −0.72 | −1.05 | −0.39 | −0.67 | 0.22 | ||||
| SF36: Role-Physical | −0.66 | −0.66 | −0.84 | −0.43 | −0.44 | −0.07 | ||||
| SF36: Bodily Pain | −0.86 | −0.32 | −0.55 | −0.50 | −0.53 | −0.03 | ||||
| SF36: General Health | −0.48 | −0.42 | −0.73 | −0.42 | −0.70 | 0.30 | ||||
| SF36: Vitality | −0.57 | −0.40 | −0.58 | −0.54 | −0.73 | 0.03 | ||||
| SF36: Social Functioning | −0.47 | −0.30 | −0.41 | −0.38 | −0.56 | 0.27 | ||||
| SF36: Role-Emotional | −0.44 | −0.46 | −0.61 | −0.56 | −0.58 | 0.25 | ||||
| SF36: Mental Health | −0.49 | −0.29 | −0.65 | −0.47 | −1.02 | 0.26 | ||||
| QLQ-C30: Global health status/QoL | −0.61 | −0.51 | −0.85 | −0.51 | −0.79 | −0.01 | ||||
| QLQ-C30: Physical Function | −0.58 | −0.68 | −0.95 | −0.34 | −0.63 | 0.12 | ||||
| QLQ-C30: Role Function | −0.52 | −0.50 | −0.55 | −0.31 | −0.59 | −0.05 | ||||
| QLQ-C30: Emotional Function | −0.51 | −0.27 | −0.35 | −0.35 | −1.01 | 0.27 | ||||
| QLQ-C30: Cognitive Function | −0.49 | −0.41 | −0.87 | −0.30 | −0.48 | 0.03 | ||||
| QLQ-C30: Social Function | −0.58 | −0.15 | −0.29 | −0.19 | −0.53 | 0.37 | ||||
| QLQ-C30: Fatigue | −0.57 | −0.23 | −0.25 | −0.53 | −0.86 | 0.02 | ||||
| QLQ-C30: Nausea / vomiting | −0.14 | 0.07 | −0.27 | −0.10 | −0.55 | 0.21 | ||||
| QLQ-C30: Pain | −0.58 | −0.34 | −0.40 | −0.32 | −0.27 | −0.08 | ||||
| QLQ-C30: Dyspnoea | −0.54 | −0.30 | −0.60 | −0.16 | −0.65 | 0.34 | ||||
| QLQ-C30: Insomnia | −0.34 | −0.39 | −0.43 | −0.32 | −0.50 | 0.20 | ||||
| QLQ-C30: Appetite loss | −0.05 | −0.23 | 0.29 | −0.14 | −0.63 | 0.09 | ||||
| QLQ-C30: Constipation | −0.50 | −0.03 | −0.57 | −0.05 | −0.66 | 0.04 | ||||
| QLQ-C30: Diarrhoea | −0.23 | 0.32 | 0.75 | −0.07 | 0.16 | 0.32 | ||||
| QLQ-C30: Financial problems | 0.12 | 0.63 | 0.35 | −0.16 | −0.21 | 0.36 | ||||
| IOC: Appearance concerns | −0.46 | −0.38 | −0.18 | −0.25 | −0.94 | 0.35 | ||||
| IOC: Body change concerns | −0.55 | −0.41 | −0.18 | −0.42 | −0.55 | 0.09 | ||||
| IOC: Life interferences | −0.59 | −0.16 | −0.28 | −0.54 | −0.84 | 0.16 | ||||
| IOC: Worry | −0.46 | 0.03 | 0.05 | −0.05 | −0.41 | 0.19 | ||||
| IOC: Negative Impact Scale | −0.62 | −0.19 | −0.15 | −0.35 | −0.73 | 0.21 | ||||
| PR25: Sexual activity | −0.12 | −0.32 | −0.75 | 0.05 | −0.18 | 0.38 | ||||
| PR25: Sexual functioning | −0.51 | −0.63 | −0.35 | 0.25 | 0.22 | 0.23 | ||||
| PR25: Urinary problems | −0.50 | −0.37 | −0.60 | −0.47 | −0.67 | 0.27 | ||||
| PR25: Incontinence aid problems | −0.36 | −0.74 | −0.27 | −0.43 | −0.71 | −0.30 | ||||
| PR25: Bowel problems | −0.39 | −0.30 | −0.51 | −0.02 | −0.61 | 0.16 | ||||
| PR25: Treatment related symptoms | −0.34 | −0.27 | −0.51 | −0.54 | −0.44 | −0.01 | ||||
Effect sizes are displayed in bold in those cases where the known groups differed significantly (p ≤ .05). A positive effect size reflects better HRQoL than the reference group, and a negative effect size reflects worse HRQoL than the reference group. areference group. PCa = prostate cancer